Burnett Patrick sold $30K of ARQT
Burnett Patrick (EVP, Chief Medical Officer) sold 943 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $31.86 on 2026-11-02.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh, primary information but is modest in scale, offering limited trading impetus.
Market read
A small insider sell that may cause slight short‑term pressure but is unlikely to drive significant market moves.
What to watch
The transaction size is small relative to total holdings and may not affect liquidity.
Background
Form 4 filing from the SEC discloses an insider transaction by Arcutis Biotherapeutics' EVP and Chief Medical Officer.
Ticker impact
CFO Burnett Patrick sold 943 shares of Arcutis Biotherapeutics for $30K, reducing his stake to 116,649 shares.
likely modest downward pressure as the market prices the insider sell.
A C-level insider sold a modest amount; while not large, such sales often prompt short-term caution.
Market effects
Minimal impact on the biotech sector; insider sales are common and rarely shift sector sentiment.
No broader regional effect; the filing is company‑specific.
Limited relevance to global markets.
Counterpoint
The sale could be routine portfolio rebalancing and not indicative of future performance.
Key entities
- CompanyArcutis Biotherapeutics, Inc.
US‑listed biotech company (ticker ARQT).
- ExecutiveBurnett Patrick
EVP, Chief Medical Officer of Arcutis Biotherapeutics.

